Drug Profile
Bocidelpar - Mitobridge
Alternative Names: ASP-0367; MA-0211; MTB-1Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Mitobridge
- Developer Astellas Pharma; Mitobridge
- Class Fluorinated hydrocarbons; Hexanoic acids; Imidazoles; Phenyl ethers; Small molecules; Urologics
- Mechanism of Action Peroxisome proliferator-activated receptor delta modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Mitochondrial myopathies
- Phase II Chronic fatigue syndrome
- Phase I Duchenne muscular dystrophy
- No development reported Metabolic disorders
- Discontinued Hypoxia
Most Recent Events
- 16 Feb 2024 phase-I development in Duchenne muscular dystrophy is ongoing in USA (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In adolescents, In children) in USA (PO)
- 19 Jul 2023 Phase-II clinical trials in Chronic fatigue syndrome (unspecified route) ((Mitobridge pipeline; July 2023))